This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ma, S. et al. Hippo signalling maintains ER expression and ER+ breast cancer growth. Nature, https://doi.org/10.1038/s41586-020-03131-5 (2021).
Britschgi, A. et al. The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα. Nature 541, 541–545 (2017).
Zhao, B., Li, L., Tumaneng, K., Wang, C. Y. & Guan, K. L. A coordinated phosphorylation by LATS and CK1 regulates YAP stability through SCFβ-TRCP. Genes Dev. 24, 72–85 (2010).
Totaro, A., Panciera, T. & Piccolo, S. YAP/TAZ upstream signals and downstream responses. Nat. Cell Biol. 20, 888–899 (2018).
Rossi, A. et al. Genetic compensation induced by deleterious mutations but not gene knockdowns. Nature 524, 230–233 (2015).
Duss, S. et al. Mesenchymal precursor cells maintain the differentiation and proliferation potentials of breast epithelial cells. Breast Cancer Res. 16, R60 (2014).
Author information
Authors and Affiliations
Contributions
A.B., J.P.C. and M.B.-A. wrote the response. The author list for this Reply differs from the author list of the original Article to accelerate the response to the Comment.
Corresponding author
Ethics declarations
Competing interests
A.B. is an employee of Roche Pharma AG and J.P.C. of Novartis. M.B.-A. and A.B. are inventors on the US patent WO2016046768A1 ‘Lats and breast cancer’.
Rights and permissions
About this article
Cite this article
Britschgi, A., Couto, J.P. & Bentires-Alj, M. Reply to: Hippo signalling maintains ER expression and ER+ breast cancer growth. Nature 591, E11–E12 (2021). https://doi.org/10.1038/s41586-020-03132-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41586-020-03132-4
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.